ArticleResearch square2026
A pH-driven receptor switch from ACE2 to NPC1 enables endosomal entry of SARS-CoV-2.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
SARS-CoV-2 enters cells either by TMPRSS2-mediated fusion at the cell surface or by cathepsin-dependent fusion from late endosomes, yet how spike remains competent for fusion during endocytic trafficking is unclear. Here we identify Niemann-Pick C1 (NPC1) as an essential intracellular receptor that enables spike-mediated fusion in acidic late endosomes/lysosomes. Genetic ablation or pharmacological inhibition of NPC1 selectively blocked endosomal entry but not the surface entry, and Omicron showed heightened NPC1 dependence consistent with reduced fusogenicity and preferential endosomal entry in cell culture. A bimolecular fluorescence complementation assay localized spike-NPC1 complexes to Rab7/LAMP1-positive compartments. Biochemical and competition analyses, supported by structural modelling, revealed that NPC1 loop C engages a surface on the receptor-binding domain distinct from the ACE2 interface and binds with higher affinity under acidic conditions, whereas ACE2 binding is favored at neutral pH. These findings define a pH-driven receptor switch from ACE2 to NPC1 during endocytic entry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.